Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Fineline Cube Jan 29, 2026
Company Deals

WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases

Fineline Cube Jan 29, 2026
Company Deals

NeuShen Therapeutics Raises Series A+ for CNS Drug Development

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026
Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Fineline Cube Jan 29, 2026
Company Drug

Shanghai Procurement Platform Offers Price Cut Leeway to Escape ‘High-Priced Drugs’ Tag

Fineline Cube Feb 7, 2024

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) platform has announced a significant policy shift regarding non-winning...

Company Drug

BioNTech and Duality’s DB-1305 Earns Fast-Track Status for Platinum-Resistant Cancers

Fineline Cube Feb 7, 2024

German biotechnology company BioNTech SE (NASDAQ: BNTC) and its partner Duality Biologics (Suzhou) Co., Ltd...

Policy / Regulatory

NMPA Reports Record 61 Innovative Medical Device Approvals in 2023

Fineline Cube Feb 6, 2024

The National Medical Products Administration (NMPA) has released its 2023 medical device filings work report,...

Company Deals

Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion

Fineline Cube Feb 6, 2024

Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical...

Company Deals

Bayer Partners with TetraScience to Enhance Data Management in Product Development

Fineline Cube Feb 6, 2024

Germany-based Bayer (ETR: BAYN) has announced a partnership with data management firm TetraScience to collect...

Company Deals

Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical

Fineline Cube Feb 6, 2024

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development...

Company Deals

Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity

Fineline Cube Feb 6, 2024

Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...

Company Drug

MSD’s Keytruda Secures 13th Indication Approval in China for Biliary Carcinoma Treatment

Fineline Cube Feb 6, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced that...

Company Medical Device

Peijia Medical’s Taurus Atlas Pro Balloon Dilation Catheter Approved by NMPA for Pulmonary Valve Procedures

Fineline Cube Feb 6, 2024

Peijia Medical Ltd (HKG: 9996) has announced that it has received marketing approval from the...

Company

MicroPort CRM Receives NMPA Approval for Next-Generation MRI-Safe Implantable Cardiac Pacing System

Fineline Cube Feb 6, 2024

MicroPort Scientific Corp. (HKG: 0853), a leading Shanghai-based medical device company, has announced that its...

Company Deals

Jiangsu Wuzhong Pharmaceutical Partners with SPH KDL Health to Boost Aesthetics Product AestheFill

Fineline Cube Feb 6, 2024

Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a leading Chinese pharmaceutical company, has announced a...

Company Drug

Konruns Pharmaceutical Commences Phase III Clinical Trial for KC1036 in Esophageal Cancer

Fineline Cube Feb 6, 2024

Konruns Pharmaceutical Co., Ltd (SHA: 603590), a Beijing-based pharmaceutical company, has announced the first patient...

Company Deals

Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea

Fineline Cube Feb 6, 2024

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with...

Company Deals

Abbisko Therapeutics Secures $70 Million Upfront Payment in Licensing Deal with Merck KGaA

Fineline Cube Feb 6, 2024

Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has declared the successful conclusion of...

Company Drug

Joincare Pharmaceuticals Gets Green Light for Semaglutide Biosimilar Clinical Trial

Fineline Cube Feb 6, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical entity, has announced that...

Company

Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues

Fineline Cube Feb 6, 2024

Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the...

Company Drug

CSPC Pharmaceutical’s rhTNK-tPA Gets NMPA Approval for Acute Ischemic Stroke Treatment

Fineline Cube Feb 5, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Roche’s Faricimab Shows Sustained Vision Benefits in Phase III Study for Retinal Vein Occlusion

Fineline Cube Feb 5, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has released interim Phase III data for its bispecific...

Policy / Regulatory

CDE Reports 35.84% Increase in Drug Filings for 2023 with Focus on Innovation and Rare Diseases

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) has released its annual drug review report for 2023,...

Company Drug

J&J’s Gene Therapy for X-linked Retinitis Pigmentosa Receives CDE Nod for Breakthrough Designation

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...

Posts pagination

1 … 353 354 355 … 616

Recent updates

  • United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial
  • Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China
  • Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform
  • Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered
  • WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.